The Evolving Role of Botulinum Toxin in Clinical Therapeutics

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".

Deadline for manuscript submissions: closed (15 June 2025) | Viewed by 429

Special Issue Editors


E-Mail Website
Guest Editor
Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
Interests: movement disorders; dystonia; botulinum toxin; focal hand dystonia, musician’s dystonia; pain
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Movement Disorders Program, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV 89106, USA
Interests: movement disorders; Parkinson’s disease; ataxia; botulinum toxin; deep brain stimulation; medical education; clinical neurophysiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to a pivotal Special Issue of the Toxins journal, entitled “The Evolving Role of Botulinum Toxin in Clinical Therapeutics”. Ongoing expansion of botulinum toxin utilization for multiple indications makes it timely to bring together a compilation of studies delineating the important role botulinum toxin now plays in clinical therapeutics as well as the development of new clinical uses for botulinum toxin and new toxin formulations and modifications.

We welcome submissions that delve into the latest research, innovative treatments, and comprehensive reviews on this topic. Areas of particular interest include but are not limited to the following:

  • Emerging uses for toxins in under-explored conditions;
  • Discussions of mechanisms of action and how these inform toxin usage in specific disorders;
  • Factors predictive of therapeutic success or risk factors for failure of response in specific settings;
  • How best to integrate botulinum toxin with other treatment modalities;
  • Discussing innovative approaches, existing challenges, and future directions in the therapeutic application of the botulinum toxin;
  • Long-term effects and quality of life for patients undergoing botulinum toxin therapy.

We would greatly appreciate submissions of original research papers and comprehensive reviews. Your expertise will significantly contribute to advancing the utilization of botulinum toxin in clinical care, to the benefit of patients worldwide.

Dr. Barbara Karp
Dr. Zoltan Mari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • botulinum toxin
  • therapeutics
  • dystonia
  • spasticity
  • aesthetics
  • pain
  • migraine
  • headache
  • achalasia
  • sphincter dysfunction
  • strabismus
  • hyperhidrosis
  • hemifacial spasm
  • tics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 10456 KiB  
Article
Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Melasma in Two Different Dilutions: A Randomized Double-Blind Split-Face Study
by Juthapa Pongklaokam, Woraphong Manuskiatti, Rungsima Wanitphakdeedecha, Pitchaya Maneeprasopchoke, Panwadee Thongjaroensirikul, Yanin Nokdhes, Rona Maria R. Abad-Constantino, Woramate Bhorntarakcharoen, Sariya Sittiwanaruk and Thanya Techapichetvanich
Toxins 2025, 17(7), 349; https://doi.org/10.3390/toxins17070349 - 11 Jul 2025
Viewed by 25
Abstract
Background: Melasma is an acquired hyperpigmentation disorder with multifactorial etiologies and limited response to conventional therapies. Recent evidence suggests that Botulinum Toxin A (BoNT-A) may modulate ultraviolet (UV)-induced pigmentation and offer therapeutic benefits. Objective: We sought to evaluate the efficacy and safety of [...] Read more.
Background: Melasma is an acquired hyperpigmentation disorder with multifactorial etiologies and limited response to conventional therapies. Recent evidence suggests that Botulinum Toxin A (BoNT-A) may modulate ultraviolet (UV)-induced pigmentation and offer therapeutic benefits. Objective: We sought to evaluate the efficacy and safety of two intradermal dilutions of Letibotulinum toxin A (LetiBoNT-A) in Thai patients with melasma. Methods: In this randomized, double-blind, split-face study, 30 participants aged 32–62 years received a single intradermal injection of LetiBoNT-A, with 20 units administered per cheek. A 1:5 dilution was injected on one side of the face, and a 1:10 dilution was injected on the contralateral side. Outcomes were evaluated over a 6-month period using the Hemi-modified Melasma Area and Severity Index (Hemi-mMASI), VISIA® brown spot analysis, and quantitative assessments of skin texture. Results: Both dilutions significantly improved Hemi-mMASI scores (1:5, p = 0.043; 1:10, p = 0.002) and brown spots (1:5, p = 0.002; 1:10, p < 0.001). The 1:10 dilution showed earlier and more sustained improvements. Subgroup analysis revealed greater reductions in Hemi-mMASI scores among patients with telangiectatic melasma, particularly with the 1:10 dilution, though they were not statistically significant. Additionally, the 1:10 dilution significantly reduced pore volume, pore area, and sebum levels. One case of transient facial asymmetry was reported with the 1:5 dilution. Conclusions: LetiBoNT-A is a safe and effective adjunct in melasma treatment. The 1:10 dilution offered superior clinical outcomes. Full article
(This article belongs to the Special Issue The Evolving Role of Botulinum Toxin in Clinical Therapeutics)
Show Figures

Figure 1

Back to TopTop